Table 3.
Logistic regression results for viral load response for HIV-1 RNA <400 at 48 weeks (n=88)
| Factor | Odds ratio (95% CI) | p-value |
|---|---|---|
| Treatment group | ||
| Low-dose TPV/r: High-dose TPV/r | 1.34 (0.49–3.65) | 0.57 |
| GIQ (quartiles) | ||
| Q2: Q1 | 12.35 (2.03–75.01) | 0.01 |
| Q3: Q1 | 17.08 (2.87–101.62) | <0.01 |
| Q4: Q1 | 38.37 (5.14–286.27) | <0.01 |
| Baseline VL (copies/mL) | ||
| ≤1000: >10K-100K | 0.21 (0.01–5.75) | 0.35 |
| >1000–10K: >10K-100K | 1.94 (0.46–8.13) | 0.37 |
| >100K: >10K-100K | 0.30 (0.09–0.94) | 0.04 |
| Age group | ||
| 2-<6: 12-<18 | 2.59 (0.71–9.39) | 0.15 |
| 6-<12: 12-<18 | 0.61 (0.19–1.97) | 0.41 |
| Adherence | ||
| Each improvement of 10% | 1.23 (1.04–1.46) | 0.01 |
| GSS | ||
| 0.25–1.00: 0 | 1.46 (0.49–4.39) | 0.50 |
| 1.25–2.25: 0 | 0.33 (0.08–1.33) | 0.12 |
Low-dose TPV/r = tipranavir 290 mg/m2 plus ritonavir 115 mg/m2
High-dose TPV/r = tipranavir 375 mg/m2 plus ritonavir 150 mg/m2
GIQ = genotypic inhibitory quotient
VL = viral load
GSS = genotypic sensitivity score